The first XFem Labs research project, supported by the Gates Foundation, aims to accelerate the development of non-hormonal contraceptives, in particular for women in low- and middle-income countries via BioMed X’s global talent sourcing and incubation model.

XFem Labs的首个研究项目得到了盖茨基金会的支持，目标是通过BioMed X的全球人才搜寻和孵化模式，加速非激素类避孕药的研发，特别是为低收入和中等收入国家的女性提供服务。

HEIDELBERG, Germany, October 14, 2025 / Biotech Newswire / --

德国海德堡，2025年10月14日 /生物技术新闻社/ --

BioMed X

BioMed X

today announced the launch of

今天宣布推出

XFem Labs

XFem实验室

, a new Women’s Health R&D Accelerator in Heidelberg. The purpose of this initiative, which is supported by the Gates Foundation, is to establish a world-class women’s health innovation hub that advances early-stage research into scalable solutions for women in need around the world, including low- and middle-income countries..

，一个位于海德堡的全新女性健康研发加速器。这项由盖茨基金会支持的倡议旨在建立一个世界级的女性健康创新中心，将早期研究转化为可扩展的解决方案，惠及全球包括低收入和中等收入国家在内的有需要的女性。

Embedded within the academic environments of the University of Heidelberg and Yale, and directly within R&D campuses of leading pharmaceutical companies, BioMed X bridges the translational gap between academia and industry to drive transformative innovation.

嵌入在海德堡大学和耶鲁大学的学术环境，以及领先制药公司的研发园区内，BioMed X 弥合了学术界与产业界之间的转化差距，推动变革性创新。

The first project at the new XFem Labs accelerator in Heidelberg is entitled “New Strategies for Female-Controlled Non-Hormonal Contraception”. Despite the availability of various contraceptive methods, 257 million women worldwide still face significant barriers to access. Current hormonal contraceptives are often associated with side effects, such as changes in bleeding patterns, resulting in high discontinuation rates.

海德堡XFem Labs新加速器的第一个项目名为“女性可控的非激素避孕新策略”。尽管有各种避孕方法可供使用，全球仍有2.57亿女性面临显著的获取障碍。当前的激素类避孕药常常伴有副作用，例如出血模式的改变，导致高停用率。

Non-hormonal, female-controlled alternatives remain limited and often challenging, hence there is an urgent need for new options..

非激素类、女性可控的替代方案仍然有限且常常具有挑战性，因此迫切需要新的选择。

The first XFem Labs call for application invites proposals that explore new biological targets, molecular mechanisms, or delivery modalities for continuous and/or on-demand non-hormonal contraception. Selected researchers will participate in a boot camp at BioMed X, resulting in the incubation of a new research team based In Heidelberg..

XFem Labs 的首个项目申请邀请探索新的生物靶点、分子机制或递送模式的提案，以实现连续和/或按需非激素避孕。获选研究人员将参加在 BioMed X 举办的训练营，从而在海德堡孵化出一个新的研究团队。

“Our joint goal with the Gates Foundation is to create a significant impact on the lives and health of women world-wide,”

“我们与盖茨基金会的共同目标是为全世界妇女的生活和健康创造重大影响，”

said Dr. Christian Tidona, CEO of BioMed X

BioMed X 首席执行官克里斯蒂安·蒂多纳博士说

. “Together with an international network of top experts and key opinion leaders, we will jointly build and mentor new outstanding research teams who will strive to solve some of the most pressing challenges in women’s health.”

“与国际顶尖专家和关键意见领袖的网络合作，我们将共同建设和指导新的优秀研究团队，努力解决女性健康领域一些最紧迫的挑战。”

Researchers interested in becoming part of this new research group are invited to respond to this international call by submitting a project proposal via the BioMed X Career Space at

有兴趣成为这个新研究小组一员的研究人员受邀通过BioMed X职业空间提交项目建议书，以响应这一国际号召。

https://career.bmedx.com/call/2025-XFL-C01

https://career.bmedx.com/call/2025-XFL-C01

before December 7, 2025.

2025年12月7日之前。

This first XFem Labs project is made possible with a $2 million grant and network support from the Gates Foundation.

XFem Labs的首个项目得以实现，得益于盖茨基金会提供的200万美元资助及网络支持。

For high resolution please click the image.

为了获得高分辨率，请点击图像。

About

关于

BioMed X

BioMed X

BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. We operate at the interface between academia and industry, performing biomedical research and drug discovery & development in the fields of oncology, immunology, neuroscience, women’s health, cardiometabolic diseases, platform technologies, and artificial intelligence..

BioMed X 是一家独立的研究机构，在德国海德堡、康涅狄格州纽黑文、康涅狄格州里奇菲尔德的 XSeed 实验室以及全球范围内的合作伙伴地点设有站点。我们立足于学术界与产业界的交汇点，致力于在肿瘤学、免疫学、神经科学、女性健康、心代谢疾病、平台技术以及人工智能领域开展生物医学研究和药物发现与开发。

All our research projects are supported by leading pharmaceutical companies or other external funding sources and conducted by early-career scientists recruited from the best schools around the world. The combination of global crowdsourcing with local incubation of the best research talents and ideas allows us to solve the biggest challenges in biomedical research..

我们所有的研究项目都得到了领先的制药公司或其他外部资金来源的支持，并由从世界各地最优秀的学校招聘的早期职业科学家开展。将全球众包与本地孵化最优秀的人才和创意相结合，使我们能够解决生物医学研究中最大的挑战。

We stand for free, creative, and curiosity-driven research combined with a solid validation of results, timelines, and deliverables. We serve a large purpose in advancing translational biomedicine by leveraging synergies and fostering cross-pollination across disciplines.

我们致力于自由、创造性和好奇心驱动的研究，并结合对结果、时间表和可交付成果的坚实验证。我们通过利用协同效应，促进跨学科的交叉融合，在推动转化生物医学方面发挥着重要作用。

Link to the

链接到

German version

德语版本

.

。

Contact

联系

BioMed X

BioMed X

Maria Morganti

玛丽亚·莫甘蒂

VP Head of Marketing & Communications

营销与传播副总裁

+49 6221 42611 30

+49 6221 42611 30

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到防垃圾邮件机器人的保护。您需要启用 JavaScript 才能查看它。

Keywords: International Cooperation; Biomedical Research; Contraceptive Agents, Female; Contraceptives, Oral, Hormonal; BioMed X; XFem Labs; Women’s Health R&D Accelerator; Heidelberg; Gates Foundation; non-hormonal contraceptives; female-controlled contraception; on-demand contraception; boot camp; research incubation; Dr.

关键词：国际合作；生物医学研究；女性避孕药；激素类口服避孕药；BioMed X；XFem Labs；女性健康研发加速器；海德堡；盖茨基金会；非激素类避孕药；女性可控避孕；按需避孕；训练营；研究孵化；博士。

Christian Tidona; international network; women’s health innovation; BioMed X Career Space; $2 million grant.

克里斯蒂安·蒂多纳；国际网络；女性健康创新；BioMed X职业空间；200万美元资助。

Source: Biotech Newswire

来源：生物技术新闻专线